Product Images Dofetilide

The text provides instructions related to administering dofetilide, a medication used for heart arrhythmias. It outlines the importance of placing the patient on telemetry and checking their baseline QTc or QT. However, it warns against using dofetiide for a patient with a QTc <440 msec. The text offers guidelines for dosing based on the patient's Calculated Creatinine Clearance (Cler) and cautions against giving dofetiide if the Cler is <20 mI/min. Post-Dose adjustment guidelines are provided based on the percentage of increase in QTc or QT after the second dose. The text instructs to discontinue dofetilide if at any point after the second dose QTc or QT increases >500 msec.*

This appears to be a graph or chart showing the probability of remaining in normal sinus rhythm (NSR) over time for different dosages of a medication called Dofet. The dosage levels are listed as 125 mcg, 250 mcg, and 500 mcg, taken twice a day (BID). There is also a line indicating the p-values obtained from a Log Rank Test. However, without additional context, it is difficult to determine the specific purpose or implications of this information.*

The text describes the mean change in QTc from baseline, measured in millisecond (msec), and the mean plasma concentration of Dofetilide (measured in ng/mL) on Day 1 and Day 23 (Steady State) during a study. No further information is available.*

This appears to be a table displaying QTc (a measurement of heart rate) changes from baseline at steady state for different doses of dofetilide medication and a placebo. The table also includes the probability of remaining in normal sinus rhythm (NSR) at 6 months for each dose. There is no information available about the study's purpose, sample size, or other research data.*

The text cannot be evaluated as it consists of random and unrelated characters and texts.*

BronPHARMA dispenses 60 capsules of Dofetilide, each containing 250 mcg (0.25 mg) as a treatment for abnormal heart rhythms. The NDC code is 69452-132.17.*